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Introduction: Pulmonary alveolar proteinosis is characterized by accumulation of surfactant and phospholipids in
the pulmonary alveoli. Whole lung lavage is considered the first-line therapy, which requires special techniques.
To the best of our knowledge, there have only been limited reports that have demonstrated the effectiveness of
ambroxol on a mild case of pulmonary alveolar proteinosis.
Case presentation: A 72-year-old Japanese woman presented to our hospital with a one-year history of productive
cough and progressive dyspnea. Her chest computed tomography scan showed a bilateral crazy-paving pattern in
both of her lungs. She was diagnosed with autoimmune pulmonary alveolar proteinosis based on bronchoalveolar
lavage findings and the presence of serum anti-granulocyte macrophage colony-stimulating factor antibodies. She was
severely hypoxemic, so we recommended whole lung lavage or inhaled granulocyte macrophage colony-stimulating
factor treatment, which she refused. We initiated treatment with ambroxol and her symptoms markedly improved.
Conclusions: Although whole lung lavage is the first-line therapy for pulmonary alveolar proteinosis, oral ambroxol
could be an alternative treatment option, even in patients with severe respiratory compromise.
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Pulmonary alveolar proteinosis (PAP) is a rare interstitial
disease caused by accumulation of surfactant and phospho-
lipids in the pulmonary alveoli, resulting in dyspnea, cough,
fatigue, and a crazy-paving pattern on chest computed
tomography (CT) [1]. PAP is classified as autoimmune or
non-autoimmune, including secondary and congenital PAP;
more than 90% of cases are diagnosed as autoimmune
PAP [2]. The pathogenesis of autoimmune PAP involves a
neutralizing antibody that directly binds to granulocyte-
macrophage colony-stimulating factor (GM-CSF) and
blocks its binding to GM-CSF receptors on cells, which
leads to inhibition of signaling, thereby inhibiting sur-
factant maturation [3]. Although whole lung lavage
(WLL) remains the current standard of care for PAP,
other therapies, including inhaled GM-CSF, rituximab,* Correspondence: nao.oda7221@gmail.com
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dies have reported that ambroxol, a commonly used ex-
pectorant, can relieve PAP [6,7]. Here, we report a case of
autoimmune PAP with chronic severe hypoxemia, which
responded to oral administration of ambroxol.Case presentation
A 72-year-old Japanese woman presented to our hospital
with a one-year history of productive cough and pro-
gressive dyspnea on exertion. Her past medical history
included only osteomyelitis at 35-years-old and she was
not taking any medications. She had never smoked or
inhaled dust as an occupational hazard. Her vital signs
were as follows: body temperature of 36.6°C, blood pres-
sure of 130/80mmHg, heart rate of 67 beats/min, and
SpO2 level of 80% (room air). Her arterial blood gas ana-
lysis revealed a pH of 7.44, PaO2 level of 43.2mmHg,
PaCO2 level of 39.2mmHg, and HCO3
− level of 26.4mEq/L
on room air. Her chest radiographs (CXR) showed bilateralis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Chest radiographs before and after the treatment. (A) Chest radiographs (CXR) on admission. (B) CXR findings improved after one
month of treatment with ambroxol.
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and her chest CT scan showed bilateral ground glass
opacities with thickened interlobular septa, an appearance
known as the ‘crazy-paving’ pattern (Figure 2A).
Her laboratory tests revealed a normal complete blood
count, high lactate dehydrogenase (543/mL), and high
Krebs von den Lungen-6 level (16,189U/mL). Her pul-
monary function tests taken on admission revealed a
vital capacity (VC) of 1.49L, %VC of 68.6%, forced ex-
piratory volume in one second (FEV1) of 1.17L, FEV1/
forced vital capacity (FVC) predicted ratio of 76.0%, and
FEV1/FVC actual ratio of 84.2%. We retrieved 26/100mL
of bronchoalveolar lavage fluid (BALF), which was milky
in appearance. Her BALF total cell count was 6.0×104/mL;
cell differentiation revealed 23% neutrophils, 1% eosi-
nophils, 17% lymphocytes, and 59% macrophages. Her
BALF contained copious eosinophilic, periodic acid Schiff-
positive granular material, a finding that supported a diag-
nosis of PAP. In addition, a high level of anti GM-CSF
antibody was detected in her serum (57.5μg/mL), leading
to a diagnosis of autoimmune PAP. Her disease severity
score (DSS) was classified as DSS 5, based on severe
hypoxemia (PaO2 level of 43.2mmHg).
Considering her severe DSS, we recommended treat-
ment with WLL under general anesthesia or inhaledFigure 2 Chest computed tomography (CT) scan before and after the trea
months of treatment with ambroxol showed almost no abnormal shadowsGM-CSF therapy. However, she refused both treatments
because of concern about complications and medical
costs; she also refused hospitalization. Therefore, we
started domiciliary oxygen therapy and an alternative
treatment of 45mg/day of ambroxol (TEIJIN PHARMA,
Tokyo, Japan). She was discharged, with frequent sche-
duled checkup examinations at our outpatient clinic. A
few days after starting ambroxol, she showed loosened
phlegm and reduced cough, with progressively impro-
ving dyspnea. Her oxygen saturation level in room air
rose to 95%, and her CXR results showed improvement
after one month (Figure 1B). Her chest CT scan after
five months of treatment showed almost no abnormal
shadows (Figure 2B), and her pulmonary function was
improved (VC of 1.88L and %VC of 90.4%). She has con-
tinued ambroxol treatment for 17 months without dis-
ease progression.
Discussion
PAP is a rare lung disease characterized by the intra-
alveolar accumulation of surfactant lipids and proteins,
which impairs gas exchange and results in respiratory
failure [3]. The majority of PAP is autoimmune PAP.
Dranoff et al. found that an absence of local GM-CSF-
dependent activation of macrophage in the lungs istment. (A) Chest CT scan on admission. (B) Chest CT scan after five
.
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now considered to occur via a neutralizing antibody,
which inhibits GM-CSF binding to receptors [3]. This
leads to a defect of alveolar macrophages and abnormal
surfactant metabolism, which results in intra-alveolar ac-
cumulation of surfactant. WLL, the standard therapy for
PAP, has beneficial effects in approximately two thirds
of patients, however, it requires special techniques and
carries the risk of complications, including hypoxemia,
hydropneumothorax, acute respiratory distress syndrome,
and post-procedure infections [1]. Inhaled GM-CSF has
also been reported as effective therapy; Tazawa et al. con-
ducted a phase II trial of GM-CSF therapy for PAP [9]. Of
35 patients completing GM-CSF therapy, 24 improved,
resulting in an overall response rate of 62% (24 out of 39;
intension-to-treat analysis). The safety and efficacy of ritu-
ximab and plasmapheresis in PAP patients is now being
studied [1]. Our patient was a candidate for WLL and in-
haled GM-CSF treatment because she had severe hypo-
xemia and was classified as DSS 5 [1]. However, she
refused our recommendations because she feared compli-
cations and medical costs, so we chose conservative treat-
ment with ambroxol.
The potential effects of ambroxol for PAP can be eva-
luated based only on limited case reports, because con-
trolled trials have not been conducted. Diaz et al. first
reported the use of ambroxol in a PAP patient in 1984,
with inhalation of 30mg of ambroxol every six hours,
leading to resolution of symptoms and improvement in
CXR findings and pulmonary function tests [7]. How-
ever, details about the patient’s characteristics were not
described. Only three additional articles about the effi-
cacy of ambroxol for PAP are available in the PubMed
database in English. Hashizume described improvement
in a patient with mild PAP (PaO2 level of 61.3mmHg
versus 43.2mmHg in our patient) treated with 45mg/day
of ambroxol [6]. Mahut et al. described a pediatric pa-
tient who experienced a 10-year remission from PAP
with ambroxol treatment, but the report concluded that
the remission might have been spontaneous [10]. Garcia
et al. reported the unsuccessful treatment of two PAP
patients with oral ambroxol [11]. It remains unclear
which patients will benefit from ambroxol and how
ambroxol affects the pathophysiology of PAP. Ambroxol
may act on type II pneumocytes, which leads to chemi-
cophysical and functional changes in alveolar macro-
phages, probably through an improvement in surfactant
secretion and uptake system [12]. We hypothesize that
this may improve PAP.
Our patient was successfully treated with oral ambroxol,
despite the severity of her disease. Though WLL or in-
haled GM-CSF therapy remains the first-line therapy for
PAP, oral ambroxol could be an alternative treatment op-
tion for patients with PAP who have severe respiratorycompromise, especially if WLL and inhaled GM-CSF
therapy is not feasible, as it is a simple treatment and with
few side effects.
Spontaneous resolution occurs in an estimated 7.9% of
PAP patients [13]. However, spontaneous resolution in
patients with a PaO2 level of less than 60mmHg is con-
sidered very rare [6]. Our patient had a PaO2 level of
43.2mmHg and her symptoms had been worsening for
more than a year leading to a diagnosis at the most se-
vere stage of the disease. Furthermore, her symptoms
immediately improved after initiating ambroxol. Hence,
we reasonably conclude that ambroxol, not spontaneous
resolution, contributed to the relief of her PAP.
Conclusions
Ambroxol can improve PAP, even in patients with severe
respiratory compromise. Although WLL is the first-line
therapy for PAP, oral administration of ambroxol should
also be considered.
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